M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the ...

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her ...

The pandemic caused an overall decrease in the rates of the 10 most common ophthalmic procedures performed in 2020 when ...

Sunita Radhakrishnan, MD, shares insights on the use of electric neurostimulation and its potential use in the treatment of glaucoma, as evidenced by its current use in Europe and the upcoming trials ...

Shan Lin, MD, speaks to the new MIGS entering the glaucoma space and providing additional options for patients and providers ...

Andrew Iwach, MD, co-founder of the Glaucoma 360 meeting shares that value this meeting has for residents and fellows as they embark on their careers and the future additions to the meeting that will ...

Inder Paul Singh, MD, speaks to the potential of artificial intelligence (AI) in the management of the glaucoma disease state ...